ClinicalTrials.gg
CompletedNCT01370603Updated Feb 9, 2022Results posted

A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)

A Phase 3 interventional study of Atorvastatin and Ezetimibe in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2022-02-09.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
328
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
27th of 97
328 · median 148
Started
2011
with 2 others
Phase 3
50 of 98
1 open now
Registered
64th of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 27th largest by enrollment of the 97 interventional ones that give a count, is one of 3 that started in 2011, is one of 50 in phase 3, and was the 64th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether ezetimibe/atorvastatin 10 mg/40 mg combination tablet is equivalent to the coadministration of ezetimibe 10 mg and atorvastatin 40 mg in lowering low-density-lipoprotein-cholesterol (LDL-C) after 6 weeks of treatment.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At low, moderate, or moderately high cardiovascular risk (according to National Cholesterol Education Program adult treatment panel III [NCEP ATP III] guidelines) and either statin-naïve with LDL-C ≥130 mg/dL for low risk or ≥100 mg/dL for moderate or moderately high risk OR on an allowable statin with on-therapy LDL-C ≥100 mg/dL in acceptable range and can safely discontinue and switch to study medication.
  • Is willing to maintain a cholesterol-lowering diet throughout the study.
  • Female of agrees to remain abstinent or to use (or have their partner use) 2 acceptable methods of throughout the study.
  • Female receiving non-cyclical hormone therapy, if maintained on a stable dose and regimen for at least 8 weeks prior to the study and if willing to continue the same regimen throughout the study.
  • Off-therapy LDL-C levels are: for low risk patients, ≥130 mg/dL and ≤300 mg/dL; for moderate risk patients, ≥100 mg/dL and ≤300 mg/dL; for moderately high risk patients, ≥100 mg/dL and ≤275 mg/dL.
  • Has liver transaminases ≤2 X (ULN) with no active liver disease.
  • Has creatine kinase (CK) levels ≤3 X ULN.
  • Has triglyceride (TG) concentrations ≤400 mg/dL.

Exclusion criteria

Exclusion criteria:

  • or intolerance to ezetimibe, atorvastatin, the ezetimibe/atorvastatin combination tablet, or any component of these medications, or a history of myopathy or rhabdomyolysis with ezetimibe or any statin.
  • Routinely consumes more than 2 alcoholic drinks per day (average >14 alcoholic drinks per week).
  • Is pregnant or lactating.
  • Has been treated with any other drug within 30 days of the study.
  • Is high risk (according to NCEP ATP III guidelines), including but not limited to one or more of the following: diabetes mellitus (Type I or II), myocardial infarction, coronary artery bypass surgery, angioplasty, stable or unstable angina.
  • Has any of the following medical conditions: congestive heart failure; uncontrolled cardiac arrhythmias or recent significant changes in an (ECG); homozygous familial hypercholesterolemia or has undergone LDL apheresis; partial ileal bypass, gastric bypass, or other significant intestinal malabsorption; uncontrolled hypertension; kidney disease; disease known to influence serum lipids or lipoproteins; hematologic, digestive, or central nervous system disorder; known to be (HIV) positive; history of ≤5 years prior to the study, except for adequately treated basal cell or squamous cell skin cancer or in situ

cervical cancer; mental instability, drug/alcohol abuse within the past 5 years, or major psychiatric illness not adequately controlled and stable on pharmacotherapy.

  • Taking prohibited medications/foods including: systemic azole antifungals (e.g., fluconazole, ketoconazole), erythromycin or clarithromycin, and cyclosporine; ritonavir and saquinavir or lopinavir; >5 cups of grapefruit juice per day; combination therapies of ezetimibe + atorvastatin (10/80 mg) or ezetimibe + rosuvastatin (10/20 mg or 10/40 mg); non-statin lipid-lowering agents including fish oils containing >900 mg/day of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA), red yeast extract, Cholestin™, bile acid sequestrants, other cholesterol-lowering agents, niacin (>200 mg/day), or fibrates; systemic ; psyllium, other fiber-based laxatives, phytosterol margarines, and/or over the counter (OTC) therapies known to affect serum lipid levels; orlistat or other anti-obesity medications and not maintained on a stable dose; any cyclical hormones; warfarin treatment without a stable dose or a stable (INR).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
328 participants (actual)

Study arms

  • Active comparator
    Ezetimibe and atorvastatin

    Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including 10 mg ezetimibe, 40 mg atorvastatin, and placebo to ezetimibe/atorvastatin.

    Drug: Atorvastatin · Drug: Ezetimibe · Drug: Placebo to ezetimibe/atorvastatin

  • Experimental
    Ezetimibe/atorvastatin combination

    Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including ezetimibe/atorvastatin 10 mg/40 mg, placebo to ezetimibe, and placebo to atorvastatin.

    Drug: Ezetimibe/atorvastatin · Drug: Placebo to atorvastatin · Drug: Placebo to ezetimibe

Interventions

  • 40 mg tablet administered orally once daily

    Also known as: Lipitor®

  • 10 mg tablet administered orally once daily

    Also known as: Zetia®

  • DrugEzetimibe/atorvastatin

    Drug pages: Ezetimibe · Atorvastatin

    Ezetimibe/atorvastatin 10 mg/40 mg combination tablet administered orally once daily

    Also known as: Liptruzet®, MK-0653C

  • DrugPlacebo to atorvastatin

    Administered orally once daily

  • DrugPlacebo to ezetimibe

    Administered orally once daily

  • DrugPlacebo to ezetimibe/atorvastatin

    Administered orally once daily

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks of Treatment

    Serum LDL-C calculated using Friedewald formula at baseline and after 6 weeks of treatment in each of the 2 treatment periods.

    Time frame: Baseline and Week 6

Secondary outcomes

  1. Percent Change From Baseline in Total Cholesterol (TC) After 6 Weeks of Treatment

    Serum TC measured at baseline and after 6 week of treatment in each of the 2 treatment periods.

    Time frame: Baseline and Week 6

  2. Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks of Treatment

    Serum HDL-C measured at baseline and after 6 weeks of treatment in each of the 2 treatment periods.

    Time frame: Baseline and Week 6

  3. Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) After 6 Weeks of Treatment

    Non-HDL-C calculated at baseline and after 6 weeks of treatment in each of the 2 treatment periods.

    Time frame: Baseline and Week 6

  4. Percent Change From Baseline in Apolipoprotein (Apo) B After 6 Weeks of Treatment

    Serum Apo B measured at baseline and after 6 weeks of treatment in each of the 2 treatment periods.

    Time frame: Baseline and Week 6

  5. Percent Change From Baseline in Triglycerides (TG) After 6 Weeks of Treatment

    Serum TG measured at baseline and after 6 weeks of treatment in each of the 2 treatment periods.

    Time frame: Baseline and Week 6

07

Results

Posted Jul 10, 2013

Participant flow

Period 1
Participant flow — Period 1
MilestoneCo-administration/Combination SequenceCombination/Co-administration Sequence
Started164164
Completed150154
Not completed1410
Withdrew: Adverse event53
Withdrew: Lost to follow-up20
Withdrew: Protocol violation22
Withdrew: Withdrawal by subject55
Crossover Washout
Participant flow — Crossover Washout
MilestoneCo-administration/Combination SequenceCombination/Co-administration Sequence
Started150154
Completed141150
Not completed94
Withdrew: Adverse event21
Withdrew: Lost to follow-up20
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject41
Withdrew: Non-compliance with study drug02
Period 2
Participant flow — Period 2
MilestoneCo-administration/Combination SequenceCombination/Co-administration Sequence
Started141150
Completed138146
Not completed34
Withdrew: Adverse event14
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryPercent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks of Treatment

Serum LDL-C calculated using Friedewald formula at baseline and after 6 weeks of treatment in each of the 2 treatment periods.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Percentage Change
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks of Treatment
Percentage ChangeEzetimibe/Atorvastatin Fixed Dose CombinationCo-Administration Ezetimibe and Atorvastatin
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks of Treatment-58.9 (-60.9 to -56.9)-58.7 (-60.7 to -56.7)
Statistical analysis
  • Ezetimibe/Atorvastatin Fixed Dose Combination vs Co-Administration Ezetimibe and Atorvastatin · ANCOVA · Difference in least-squares means: -0.2 · 97.5% CI -1.9 to 1.4
SecondaryPercent Change From Baseline in Total Cholesterol (TC) After 6 Weeks of Treatment

Serum TC measured at baseline and after 6 week of treatment in each of the 2 treatment periods.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Percentage Change
Percent Change From Baseline in Total Cholesterol (TC) After 6 Weeks of Treatment
Percentage ChangeEzetimibe/Atorvastatin Fixed Dose CombinationCo-Administration Ezetimibe and Atorvastatin
Percent Change From Baseline in Total Cholesterol (TC) After 6 Weeks of Treatment-43.0 (-44.5 to -41.5)-42.9 (-44.4 to -41.4)
Statistical analysis
  • Ezetimibe/Atorvastatin Fixed Dose Combination vs Co-Administration Ezetimibe and Atorvastatin · ANCOVA · Difference in least-squares means: -0.1 · 97.5% CI -1.4 to 1.2
SecondaryPercent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks of Treatment

Serum HDL-C measured at baseline and after 6 weeks of treatment in each of the 2 treatment periods.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Percentage Change
Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks of Treatment
Percentage ChangeEzetimibe/Atorvastatin Fixed Dose CombinationCo-Administration Ezetimibe and Atorvastatin
Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks of Treatment2.3 (0.8 to 3.8)2.6 (1.2 to 4.1)
Statistical analysis
  • Ezetimibe/Atorvastatin Fixed Dose Combination vs Co-Administration Ezetimibe and Atorvastatin · ANCOVA · Difference in least-squares means: -0.3 · 97.5% CI -1.8 to 1.2
SecondaryPercent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) After 6 Weeks of Treatment

Non-HDL-C calculated at baseline and after 6 weeks of treatment in each of the 2 treatment periods.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Percentage Change
Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) After 6 Weeks of Treatment
Percentage ChangeEzetimibe/Atorvastatin Fixed Dose CombinationCo-Administration Ezetimibe and Atorvastatin
Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) After 6 Weeks of Treatment-55.4 (-57.2 to -53.5)-55.2 (-57.0 to -53.4)
Statistical analysis
  • Ezetimibe/Atorvastatin Fixed Dose Combination vs Co-Administration Ezetimibe and Atorvastatin · ANCOVA · Difference in least-squares means: -0.2 · 97.5% CI -1.7 to 1.4
SecondaryPercent Change From Baseline in Apolipoprotein (Apo) B After 6 Weeks of Treatment

Serum Apo B measured at baseline and after 6 weeks of treatment in each of the 2 treatment periods.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Percentage Change
Percent Change From Baseline in Apolipoprotein (Apo) B After 6 Weeks of Treatment
Percentage ChangeEzetimibe/Atorvastatin Fixed Dose CombinationCo-Administration Ezetimibe and Atorvastatin
Percent Change From Baseline in Apolipoprotein (Apo) B After 6 Weeks of Treatment-48.7 (-50.4 to -47.0)-48.3 (-50.0 to -46.6)
Statistical analysis
  • Ezetimibe/Atorvastatin Fixed Dose Combination vs Co-Administration Ezetimibe and Atorvastatin · ANCOVA · Difference in least-squares means: -0.5 · 97.5% CI -1.9 to 1.0
SecondaryPercent Change From Baseline in Triglycerides (TG) After 6 Weeks of Treatment

Serum TG measured at baseline and after 6 weeks of treatment in each of the 2 treatment periods.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Percentage Change
Percent Change From Baseline in Triglycerides (TG) After 6 Weeks of Treatment
Percentage ChangeEzetimibe/Atorvastatin Fixed Dose CombinationCo-Administration Ezetimibe and Atorvastatin
Percent Change From Baseline in Triglycerides (TG) After 6 Weeks of Treatment-36.2 (-40.4 to -31.6)-36.2 (-38.8 to -33.5)
Statistical analysis
  • Ezetimibe/Atorvastatin Fixed Dose Combination vs Co-Administration Ezetimibe and Atorvastatin · constrained Longitudinal Data Analysis · Difference in least-squares means: 0.0 · 97.5% CI -4.9 to 4.9

Adverse events

Collected over 18 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ezetimibe/Atorvastatin Fixed Dose Combination—3/303 (1%)0/303 (0%)
Co-Administration Ezetimibe and Atorvastatin—2/313 (0.6%)0/313 (0%)
Most frequent serious events
Most frequent serious events
EventEzetimibe/Atorvastatin Fixed Dose CombinationCo-Administration Ezetimibe and Atorvastatin
Angina unstableCardiac disorders1/3030/313
Cholecystitis acuteHepatobiliary disorders1/3030/313
SepsisInfections and infestations1/3030/313
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3030/313
Coronary artery diseaseCardiac disorders0/3031/313
Myocardial infarctionCardiac disorders0/3031/313

Baseline characteristics

Age, Customized
Age, Customized(Participants)Co-administration/Combination SequenceCombination/Co-administration SequenceTotal
30 to 39 years10919
40 to 49 years352964
50 to 59 years7461135
60 to 64 years203555
≥ 65 years253055
Sex: Female, Male
Sex: Female, Male(Participants)Co-administration/Combination SequenceCombination/Co-administration SequenceTotal
Female9492186
Male7072142
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Bays HE, Chen E, Tomassini JE, McPeters G, Polis AB, Triscari J. Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to co-administered components in randomized trials: use of a dose-response model. Fundam Clin Pharmacol. 2015 Apr;29(2):209-18. doi: 10.1111/fcp.12096. Epub 2015 Feb 27. PubMed 25431239 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2011
First posted
Jun 10, 2011
Start
Sep 2011
Primary completionActual
May 2012
CompletionActual
May 2012
Results first posted
Jul 10, 2013
Last update
Feb 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01370603
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Jun 10, 2011
Start date
Sep 2011
Primary completion
May 2012
Completion
May 2012
Results posted
Jul 10, 2013
Last update
Feb 9, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Atorvastatin

Start the discussion